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Summary
 Aim The purpose of our study was to conduct a retrospective analysis of malignant glioma patients treat-
ed with postoperative radiotherapy in order to assess the clinical outcome and identify prognostic 
factors which may alter the prognosis.
Materials/Methods We have retrospectively reviewed the medical records of 107 patients with histologically conﬁ rmed 
cerebral high grade gliomas (HGG) treated with postoperative radiotherapy from November 1997 
to December 2002 at the Department of Radiotherapy of the Holycross Cancer Centre in Kielce. 
The total dose varied from 20 Gy in 5 fractions to 62 Gy in 31 fractions. The overall survival ( OS ) 
and the progression free survival ( PFS ) were calculated by using the actuarial method according 
to Kaplan and Meier. A multivariate analysis was made using the Cox regression model to identi-
fy independent prognostic factors. The following factors were studied for the prognostic signiﬁ -
cance for OS and PFS: histology, sex, age, the WHO performance status and the neurological def-
icit status, the size and localization of the tumour before surgery, the extent of the resection, the 
time from the operation to the start of the irradiation, the total dose of radiotherapy and the re-
sponse to treatment three months from the end of radiotherapy.
 Results The overall survival (OS) was 0.38 and 0.13 at one and two years, respectively, and the progression 
free survival (PFS) was 0.13 and 0.06 at one and two years, respectively, for the whole group of the 
postoperatively irradiated patients. In the multivariate analysis: histopathology, age, performance 
and the neurological status before the onset of radiotherapy, the total dose of irradiation and the 
response to the treatment observed three months from the end of radiotherapy were found to be 
signiﬁ cant prognostic factors for the overall survival, while histopathology, age, performance and 
the neurological status at the beginning of the irradiation and the total dose of the radiotherapy 
were found to be signiﬁ cant prognostic factors for the progression free survival.
 Conclusions The prognosis for high-grade glioma patients remains poor. The combined treatment, operation 
and radiotherapy, resulted in the overall survival of 0.38 at one year and 0.13 at two years and the 
progression free survival of 0.13 at one year and 0.06 at two years in the study group. In the mul-
tivariate analysis: histopathology, age, performance and the neurological status before the onset 
of radiotherapy, the total dose of the irradiation and the response to treatment observed three 
months from the end of radiotherapy were found to be signiﬁ cant prognostic factors inﬂ uencing 
the overall survival, while histopathology, age, performance and the neurological status at the be-
ginning of the irradiation, the total dose of radiotherapy were found to be signiﬁ cant prognostic 
factors inﬂ uencing the progression free survival. The assessment of the prognostic factors is very 
important, because it is a guide to the treatment selection by clinicians.
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BACKGROUND
For the past few decades, a growing number of new cas-
es of malignant brain tumours has been observed [1]. 
Approximately 1.3% of all newly diagnosed cases of neo-
plasms in Poland in 1999 were malignant gliomas (about 1370 
patients) [1]. Malignant gliomas, which include anaplastic 
astrocytoma and glioblastoma multiforme are the most com-
mon primary brain tumours in adults, accounting for more 
than 40% of the malignancies of the central nervous system 
and occurring at a rate of ﬁ ve cases per 100.000 population 
per year. [2–4]. The medical management of patients with 
malignant gliomas still remains controversial, because of the 
poor prognosis of this clinical entity and a very unsatisfacto-
ry outcome where only palliative results can be achieved, ir-
respective of the type of the treatment employed.
In many oncological centers worldwide the standard ther-
apeutic approach for the past few decades was to combine 
the maximum neurosurgical resection of the tumour fol-
lowed by postoperative radiotherapy. The clinical application 
of chemotherapy as the primary treatment remains contro-
versial, although its role as a salvage therapy at the time of 
the progression after the ﬁ rst line treatment was found to 
be efﬁ cient in obtaining a short time improvement in ma-
lignant glioma patients [5–8]. The rationale for postoper-
ative irradiation in malignant glioma patients has been to 
postpone the tumour regrowth after surgical excision and 
therefore increase the survival. The clinical data showed 
three to six-month improvement in the overall survival due 
to postoperative radiotherapy [2,9–11]. Despite the long 
application of postoperative radiotherapy in the manage-
ment of patients suffering from malignant gliomas, many 
clinical problems connected with this sequential therapeu-
tic option still remain unanswered.
AIM
The purpose of our study was to conduct a retrospective anal-
ysis of malignant glioma patients treated with postoperative 
radiotherapy in order to assess the clinical outcome and iden-
tify prognostic factors which may alter the prognosis.
MATERIALS AND METHODS
We have retrospectively reviewed the medical records of 107 
patients with histologically conﬁ rmed cerebral high grade 
gliomas (HGG) treated with postoperative radiotherapy from 
November 1997 to December 2002 at the Department of 
Radiotherapy of the Holycross Cancer Centre in Kielce. 
Four patients were excluded from the analysis. Three of 
them were lost from the follow up immediately after radio-
therapy, and no medical record was available for the analy-
sis. The remaining patient suffered from early progression 
during the second week of radiotherapy and the irradia-
tion was stopped. He was then referred for the second op-
eration. The population under study consisted of 55 males 
and 48 females. The mean age was 53.9 years (range 18–
79 years with the standard deviation of 12.52). Initially, all 
patients were subjected to neurosurgical intervention and 
the extent of the tumour resection was determined from 
operation reports. Near total resection was made in 47 pa-
tients, the subtotal and the partial resection in 54, and 2 pa-
tients underwent biopsy only. In 52 cases the tumours were 
localized in more than one lobe. The pathology report re-
vealed the glioblastoma multiforme in 73 patients (71%) 
and anaplastic astrocytoma in 30 patients (29%). The pre-
radiotherapy WHO performance status was 0 and 1 in 64 
patients, 2 in 26 patients and 3 in 13 patients. The assess-
ment of the patient’s neurological status was made accord-
ing to the EORTC/MRC Neurological Deﬁ cits Score [12] 
and in 23 cases it was 1, in 21 was 2, in 32 patients it was 3 
and in remaining 20 cases it was 4. The clinical characteris-
tics of the patients is summarized in Table 1. Postoperative 
irradiation was initiated between 0.3 and 8.2 months after 
surgery (the mean value was 1.5 and the standard deviation 
of 1.30). The patients were treated with a Co-60 unit or a 
linear accelerator with 6 or 15 MeV photons in the supine 
Characteristics Category Number (%) of patients
Sex
Males  55 (53.4%)
Females  48 (46.6%)
Age 
≤50 yrs  36 (35%)
>50 yrs  67 (65%)
≤45 yrs  22 (23.7%)
45–60 yrs  44 (47.3%)
>60 yrs  37 (35.9%)
WHO PS 
before RTH
0–1  64 (62%)
2  26 (25%)
3  13 (13%)
Neurological 
deﬁ cit status 
before RTH
1  23 (22%)
2  21 (20%)
3  32 (31%)
4  20 (20%)
unknown  7 (7%)
Histology
GBM  73 (70.9%)
AA  30 (29.1%)
Tumour location 
(lobe)
frontal  18 (17.5%)
temporal  19 (18.5%)
parietal  13 (12.6%)
> than 1 lobe  52 (50.5%)
cerebellum  1 (1%)
Size of tumour 
≤5 cm  51 (49.5%)
>5 cm  51 (49.5%)
unknown  1 (1% )
Extent 
of operation
near total  47 (45.6%)
subtotal and partial  54 (52.4%)
biopsy  2 (1.9%)
Table 1. Patients characteristics.
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position. All patients were immobilised with thermoplastic 
masks. In all cases but three, 3-D treatment planning based 
on computed tomography (CT) scans was used. The plan-
ning target volume (PTV) encompassed the tumour bed 
with the oedema with an additional 2 cm margin around it. 
In 74 patients such a treatment was followed by a boost to 
the tumour bed with the surrounding oedema. In the stand-
ard techniques two opposed ﬁ elds with the whole brain ir-
radiation were used. The dose was calculated at an ICRU 
50 reference point. The total dose varied from 20 Gy in 5 
fractions to 62 Gy in 31 fractions. The most frequently used 
schedules of the irradiation were 60Gy in 30 fractions (62%) 
and 42 Gy in 15 fractions (18,5%).
The irradiation was combined with chemotherapy in ﬁ ve 
cases. Three patients were given temozolomide 75mg/m2/d 
× 7d/week for 6 weeks during radiotherapy, followed by ad-
juvant therapy with this drug at a dose of 200mg/m2/d × 5 
days every 28 days for six cycles. Two patients were given ad-
juvant chemotherapy only and they received 4 and 6 cycles 
of temozolomide 200mg/m2/d × 5 days every 28 days.
Acute and late radiation morbidity were scored according 
to the EORTC/RTOG scale. The response to the treatment 
based on CT or magnetic resonance (MR) was assessed in 
68 patients three months from the end of radiotherapy. In 
patients in whom relapse or progression was suspected, one 
of two diagnostic procedures had been carried out earlier. 
Twelve patients with rapid relapse manifested by clinical 
symptoms and with poor performance status did not have 
CT or MRI, and the progression was based on physical ex-
amination only. Thirty-one patients had complete response 
(CR), 20 partial response (PR) and 49 had progressive dis-
ease (PG). The response to treatment was not assessed in 3 
patients because they were lost from the follow up. Salvage 
treatment was applied in 36 (35%) cases. Thirty-three pa-
tients were managed by surgical resection at the time of the 
relapse. Eight of them were also scheduled for chemotherapy 
after being re-operated. The remaining 3 patients received 
chemotherapy, as the only salvage treatment. The chemo-
therapy regimens consisted of 1 to 3 cycles of temozolomide 
200mg/m2 × 5 days every 28 days in 7 patients, and 1 to 8 
cycles of lomustine 120mg/m2 in one day every 42 days in 4 
patients. Systemic treatment was carried on till the time of 
the progression. Fifty-seven patients were subjected to sup-
portive care only at the time of their relapse.
The overall survival (OS) and the progression free surviv-
al (PFS) were deﬁ ned as the time from the end of radio-
therapy to death and to the development of progressive dis-
ease, respectively. Both values were calculated by using an 
actuarial method according to Kaplan and Meier. A multi-
variate analysis was made using the Cox regression model 
to identify independent prognostic factors. The following 
factors were studied for the prognostic signiﬁ cance for OS 
and PFS: histology, sex, age, the WHO performance status 
and the neurological deﬁ cit status, the size and localization 
of the tumour before surgery, the extent of the resection, 
the time from the operation to the start of irradiation, the 
total dose of radiotherapy and the response to treatment 
three months from the end of radiotherapy. The statistical 
analysis was made with SAS Proprietary Software Release 
8.2 (TS2M0).
RESULTS
At the time of the analysis, 93 patient died because of local 
recurrence or progression of the tumour. The overall sur-
Figure 1. Overall survival probability curve.
Figure 2. Overall survival probability by histopathology.
Figure 3. Overall survival probability by patients’ age.
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Figure 5. Overall survival probability by WHO PS.
Figure 6. Overall survival probability by neurological status.
Figure 4. Overall survival probability by patients’ age. Figure 7. Overall survival probability by total irradiation dose.
Figure 8. Overall survival probability by response to treatment.
Figure 9. Progression free survival probability curve.
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Figure 10. Progression free survival probability by histopathology.
Figure 11. Progression free survival probability by patients’ age.
Figure 12. Progression free survival probability by patients’ age.
Figure 13. Progression free survival probability by WHO PS.
Figure 14. Progression free survival probability by neurological status.
Figure 15. Progression free survival probability by total irradiation dose.
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vival (OS) and the standard deviation for the whole group 
of the postoperatively irradiated patients was 0.38±0.05 and 
0.13±0.03 at one and two years, respectively (Figure 1). The 
median survival for all patients was 12 months. In the mul-
tivariate analysis histopathology (Figure 2), age (Figures 3 
and 4), performance (Figure 5) and the neurological sta-
tus (Figure 6) before the onset of radiotherapy, the total 
dose of the irradiation (Figure 7) and the response to the 
treatment observed three months from the end of the radi-
otherapy (Figure 8) were found to be signiﬁ cant prognos-
tic factors for the overall survival. The details of the multi-
variate analysis are presented in Table 2.
The progression free survival (PFS) and the standard de-
viation for the entire group of patients was 0.13±0.03 and 
0.06±0.02 at one and two years, respectively (Figure 9). 
1-year OS rate 2-years OS rate Mean (months) P value
Histology
GBM  0.29±0.05  0.03±0.02 9.4
0.0001
AA  0.57±0.09  0.35±0.09 18
WHO PS
0–1  0.50±0.06  0.19±0.05 14.7
<0.00012  0.23±0.08  0.05±0.05 8
3  0.08±0.07 0 6.4
Neurological status 
1–2  0.53±0.08  0.19±0.07 14.6
0.0068
3–4  0.23±0.06  0.08±0.04 9.3
Age
≤ 50 yrs  0.60±0.08  0.29±0.08 18
<0.0001
>50 yrs  0.26±0.05  0.05±0.03 8.9
≤45 yrs  0.71±0.10  0.53±0.11 22.6
<0.000145–60 yrs  0.45±0.07  0.07±0.04 12.5
>60 yrs  0.09±0.05 0 5.6
Total dose of RT
≤50 Gy  0.16±0.06  0.04±0.04 7
<0.0001
>50 Gy  0.49±0.06  0.17±0.05 14.5
Response to treatment
CR  0.73±0.08  0.25±0.08 18.8
<0.0001PR  0.45±0.11  0.30±0.11 16.3
PG  0.13±0.05 0 6.2
Table 2. Multivariate analysis of prognostic factors for overall survival.
1-year PFS rate 2-years PFS rate Mean PFS (months) P value
Histology
GBM  0.04±0.02 0 4.1
0.0001
AA  0.35±0.09  0.12±0.08 10
WHO PS
0-1  0.18±0.05  0.06±0.03 7.4
0.00122  0.08±0.06 0 4,6
3 0 0 2
Neurological status
1–2  0.20±0.06  0.07±0.04 7.5
0.0429
3–4  0.08±0.04  0.02±0.02 4.7
Age
≤50 yrs  0.29±0.08  0.12±0.06 9.7
<0.0001
>50 yrs  0.05±0.03 0 3.9
≤ 45 yrs  0.43±0.11  0.20±0.09 11.9
<0.000145–60 yrs  0.09±0.04 0 6.1
>60 yrs 0 0 2.1
Table 3. Multivariate analysis of prognostic factors for progression free survival.
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The median PFS was 6 months for all the patients as-
sessed.
Histopathology (Figure 10), patients’ age (Figures 11 and 
12), performance (Figure 13) and neurological status 
(Figure 14) at the beginning of the irradiation, total irra-
diation dose (Figure 15) were found to be signiﬁ cant prog-
nostic factors in the multivariate analysis for PFS. The de-
tails of the analysis are presented in Table 3.
Acute toxicity of the treatment was low. There were 45 (43.7%) 
cases of G0, 55 (53.4%) cases of G1 and 3 (2.9%) cases of G2 
brain toxicity. Skin toxicity appeared as G1 in 76 (67.9%) cas-
es and as G2 in 25 (24.3%) cases. The remaining 2 patients 
had no skin toxicity. All patients had partial or very rare total 
alopecia Severe late toxicity caused by radiotherapy was not 
observed but it had to be stressed that due to the very high 
rate of early relapse accompanied by mortality in every case 
reliable assessment of side effects was rarely possible.
DISCUSSION
The median overall survival (OS) and the progression free 
survival (PFS) for the group analyzed remained poor, and 
were similar to the data presented in other reports. The 
median overall survival ranged from 5 to 14 months, and 
the median progression free survival ranged from 5 to 7.5 
months [9,10,13–19]. High grade gliomas represent a het-
erogeneous group of diseases, therefore it is very impor-
tant to identify the factors that can inﬂ uence the clinical 
outcome in order to decide on the most appropriate treat-
ment strategy. The prognostic factors could be divided in 
three groups: patients, tumour and treatment variables. In 
our study, patients’ age, the neurological and performance 
status before the onset of radiotherapy were assessed to be 
statistically signiﬁ cant for both OS and PFS. The importance 
of these patients’ variables was very well documented else-
where and age [3,16,17,20–24], performance [3,9,11,14–
17,22,25] and the neurological status [9,20,26] are common-
ly accepted prognostic factors. Fifty years was the simplest 
and the most frequently used age cutoff [3,10,20], whereas 
some authors accepted a more complex division: 60 years 
as age cutoff [16] or division of patients into three groups 
with cutoffs of 45 and 60 years [11], 40 and 60 years [17]. 
We carried out age analysis using the two above mentioned 
approaches and found statistical signiﬁ cance for both age 
divisions, favouring younger patients over elderly ones. This 
supports the thesis that the patient’s age at the diagnosis 
is one of the strongest factors connected with prognosis. 
While the performance status is commonly assessed with 
the WHO scale, the neurological status is evaluated with 
different scales worldwide [11,13,27] the one most often 
used being the EORTC/MRC Neurological Deﬁ cits Score 
[12,25]. Patients in our study with poor performance and 
neurological status had statistically signiﬁ cant shorter OS 
and PFS. Both factors seemed to have a bigger impact on 
the clinical outcome in younger patients than in elderly 
ones [28]. Some authors considered the duration of the 
neurological symptoms before the diagnosis as a patient’s 
variable useful in predicting the future course of the dis-
ease [3,9,11,26]. We did not analyze this for its signiﬁ cance 
in OS and PFS, because the medical data available for our 
study did not provide us with sufﬁ cient information about 
the clinical symptoms before operation.
Among tumour variables the primary grade and tumour 
histology appear to have the greatest effect on the clinical 
outcome [16,20–24]. Glioblastoma histology predicts poor 
prognosis compared with anaplastic astrocytoma. An oli-
godendroglial component is associated with a better clini-
cal outcome in patients with grade 3 astrocytoma [29]. In 
our study, patients with diagnosed anaplastic astrocytoma 
lived twice as long as the patients with glioblastoma multi-
forme (the mean value of 18 months vs 9.4 months, respec-
tively). Other variables such as tumour size and location 
have not been shown to be signiﬁ cant prognostic factors 
either in our study or in other analyses presented in the lit-
erature [14,17,25]. There is limited data on the prognostic 
value of the proliferation and genetic markers. Some studies 
showed a signiﬁ cant correlation between the chromosom-
al abnormalities and the survival and the chemosensitivity 
in patients with anaplastic oligodendroglioma [30]. In an-
aplastic astrocytoma loss or mutation of pTEN tumour sup-
pressor gene is associated with poor survival [31].
Contrary to some authors who claim that the near total re-
section compared with biopsy only appears to be the most 
consistent prognostic factor associated with improved sur-
vival among the treatment variables [3,32], we did not ﬁ nd 
it to be the case in our analysis. The lack of correlation be-
tween OS and PFS rates and the extent of resection as ex-
plained by subjective judgment of the type of operation by 
different neurosurgeons were due to the inﬁ ltrating growth 
of high grade gliomas, the borders of this malignancy be-
ing difﬁ cult to be unequivocally assessed. It is commonly 
accepted that the delay in the initiation of postoperative ir-
radiation beyond 6 weeks after surgery worsens the progno-
sis. Although such a belief is very strong among clinicians 
there is, however, few available data to support it [16]. In 
our study the interval between the surgery and the radi-
ation was not a statistically signiﬁ cant factor inﬂ uencing 
both OS and PFS. It is commonly accepted that the opti-
mum conventional external beam radiotherapy is a 6-week 
course of treatment to a total dose of 60 Gy in 30 daily frac-
tions [2,3,5,15,33]. The shorter palliative hypofractionated 
1 to 3-week regimens gave modestly but signiﬁ cantly poor-
er outcome in malignant glioma patients [9,10,16]. In our 
study the patients irradiated with a total dose of over 50Gy 
lived twice as long as the patients who received a dose equal 
to or less than 50Gy (the mean survival of 14.5 months vs 7 
months, respectively with p<0,0001) this relatively big gain 
in the survival compared with randomized studies was prob-
ably caused by the selection of patients with poor prognos-
tic factors for hypofractionated treatment.
The survival gain of the radical compared with the pallia-
tive course of radiotherapy in patients with life expectancy 
of less than 6 months is relatively small, usually few weeks 
only. Therefore there is an opinion among radiation oncol-
ogists that it is not appropriate to offer a 6-week course of 
intensive treatment to such patients [2,9,13,14,25,26,33]. 
In our institution the patients whose life expectancy, based 
on prognostic factors, was considered to be less than six 
months, were scheduled to a hypofractionated course of 
radiotherapy, preferably to 42 Gy in 15 fractions. The as-
sessment of life expectancy is very important, because it is 
a guide to treatment selection for clinicians. None of the 
presented clinical factors can separately predict survival 
and schedule for radical or palliative treatment. Several 
institutions have developed scoring systems to deﬁ ne the 
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prognosis for high grade glioma patients: Medical Research 
Council (MRC) in the UK, Radiation Therapy Oncology 
Group (RTOG), and Gupta and Sarin [9]. All these sys-
tems can be adapted to daily routine management of ma-
lignant glioma patients but at our centre we used a RPA-
RTOG scale.
The response to treatment observed three months from 
the end of radiotherapy, based on radiological examina-
tion, was found to be a signiﬁ cant prognostic factor for 
the overall survival in the study patients. Some authors 
also considered the importance of this factor in predict-
ing life expectancy [21,34,35], and the clinical applica-
tion of this assessment could be found in the selection of 
patients with good response for salvage treatment at the 
time of the relapse. Currently, no standard of care exists 
for patients with recurrent high-grade gliomas. The ma-
jority of the study patients, at the time of their relapse, 
were under supportive care only. Salvage treatment could 
be applied to the minority of patients with a rather poor 
outcome, irrespective of the type of the treatment em-
ployed including re-operation [20,36], chemotherapy 
[24,37–39] or both [24]. Re-operation and chemother-
apy are most frequently used at the time of the relapse, 
while re-treatment with radiotherapy (stereotactic radi-
osurgery or brachytherapy) is rarely applied because of 
the cumulative toxicity and the extended growth of the 
recurrent tumour.
Several attempts have been made to improve poor results 
of the therapy of malignant glioma patients using hyper-
fractionation [2], accelerated hyperfractionation [20], con-
tinuous accelerated fractionation [17], hypofractionation 
[2,15], particle therapy including neutrons, protons, heli-
um ions etc. [2,33], hyperbaric oxygenation prior the cours-
es of radiotherapy [40], hyperthermia [41], nicotinamide 
and carbogen [42], and immunotherapy [43].
Unfortunately none of them proved to be effective in ex-
tending PFS and OS compared with standard management. 
In a very selected group of patients dose escalation with ster-
eotactic radiotherapy or brachytherapy [3,33,44] improved 
the survival. The use of chemotherapy as the postoperative 
treatment combined with radiotherapy remains controver-
sial [6,8,9,45–48]. The improvement of the outcome pre-
sented in clinical trials [49,50] and the meta-analyses [7,8] 
was very limited in the whole group of malignant glioma pa-
tients. Anaplastic oligodendroglioma histology proved to be 
the most chemo-sensitive type compared to other tumours. 
Stupp et al. have recently reported a promising overall sur-
vival rate for glioblastoma patients in phase II trial of radi-
otherapy and concomitant temozolomide [51]. The place 
of chemotherapy in the management of malignant glioma 
patients will be elucidated in near future, because the re-
sults of the European Organization for the Research and 
Treatment of Cancer phase III clinical trial of radiation with 
or without temozolomide in patients with newly diagnosed 
high-grade gliomas and the Radiation Therapy Oncology 
Group study of radiation with or without PCV chemothera-
py in newly diagnosed anaplastic oligodendroglioma should 
be reported this year [6]. The improvement of the outcome 
of the above poor prognosis requires that emphasis should 
be put on discovering novel therapies. It is therefore jus-
tiﬁ able that clinicians should enroll malignant glioma pa-
tients for clinical trials.
CONCLUSIONS
1.  The prognosis for high-grade glioma patients remains poor. 
The combined treatment, operation and radiotherapy, have 
resulted in the overall survival of 38% at one year and 13% 
at two years, and the progression free survival of 13.5% at 
one year and 6% at two years in the study group.
2.  In the multivariate analysis: histopathology, age, perform-
ance and the neurological status before the onset of radi-
otherapy, the total dose of the irradiation and response 
to treatment observed three months from the end of ra-
diotherapy were found to be signiﬁ cant prognostic fac-
tors inﬂ uencing the overall survival while histopatholo-
gy, age, performance and the neurological status at the 
beginning of the irradiation, the total dose of radiother-
apy were found to be signiﬁ cant prognostic factors inﬂ u-
encing the progression free survival.
3.  The assessment of the prognostic factors is very impor-
tant, because it is a guide to the treatment selection for 
clinicians.
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